Avelumab and Merkel Cell Carcinoma: Understanding the Evidence on Risk and Causation

From General Health to Targeted Pharmacovigilance

The legacy context of general health and science information has long provided a foundation for understanding broad population-level risks and preventive measures. Within this framework, public health communications have historically emphasized lifestyle factors, environmental exposures, and therapeutic interventions as key determinants of disease outcomes. As the field has matured, attention has increasingly turned to specific pharmaceutical agents and their potential long-term effects, particularly in oncology where immunomodulatory drugs are now widely used. This shift from general health guidance to targeted pharmacovigilance reflects a natural progression in scientific inquiry. In the domain of mass production, where occupational exposure to various compounds is a routine concern, the focus narrows further. Workers in manufacturing settings may encounter therapeutic agents or their precursors during production, handling, or quality control processes. This raises legitimate questions about whether such occupational contact could influence disease risk, including malignancies. The transition from a general health perspective to a specific occupational exposure concern thus requires careful consideration of how workplace conditions intersect with pharmaceutical safety profiles, without delving into unverified mechanistic pathways.

Avelumab: Mechanism and Approved Use in Merkel Cell Carcinoma

Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It has been approved in the United States, the European Union, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/29799096/). The approval was based on the two-part, single-arm, phase II JAVELIN Merkel 200 trial, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). Avelumab is thus the first therapeutic agent specifically approved for this indication and is approved for use independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/).

Merkel Cell Carcinoma: Etiology and Treatment Landscape

Merkel cell carcinoma is associated with chronic exposure to ultraviolet light and the Merkel cell polyomavirus, with approximately 80% of cases caused by the human Merkel cell polyomavirus and the remaining 20% induced by UV light leading to mutations (https://pubmed.ncbi.nlm.nih.gov/35877101/; https://pubmed.ncbi.nlm.nih.gov/34445385/). The incidence of MCC is increasing, and it is associated with high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Immune checkpoint inhibitors, including avelumab (anti-PD-L1) and pembrolizumab (anti-PD-1), offer durable responses and significant clinical benefit, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). However, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy, and 50% of patients do not respond or develop immune-related adverse events due to diverse mechanisms such as down-regulation of MHC complexes or the induction of anti-inflammatory cytokines (https://pubmed.ncbi.nlm.nih.gov/35877101/; https://pubmed.ncbi.nlm.nih.gov/34445385/). For patients who are refractory to avelumab, efficient and safe treatment options are lacking (https://pubmed.ncbi.nlm.nih.gov/33439294/). In a retrospective study conducted at three academic sites in Germany, clinical and molecular data of five patients with metastatic MCC refractory to avelumab who were later treated with combined ipilimumab and nivolumab were collected and evaluated; three out of five patients responded to combined therapy according to RECIST 1.1 (https://pubmed.ncbi.nlm.nih.gov/33439294/). A multicenter study of the prospective skin cancer registry ADOREG similarly reported on ipilimumab plus nivolumab in avelumab-refractory MCC (https://pubmed.ncbi.nlm.nih.gov/36450381/). A retrospective study of ipilimumab plus nivolumab in anti-PD-L1/PD-1 refractory MCC further noted that despite advances in systemic therapy, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/).

Risk Assessment: Avelumab as Treatment, Not Cause

The mechanistic pathway linking avelumab to MCC risk is not one of causation but rather of therapeutic use. Avelumab is indicated for the treatment of metastatic MCC, not as a cause of the disease. The evidence reviewed does not indicate that avelumab causes MCC; rather, it is a treatment for MCC. The risk anchors relevant to this analysis include the adequacy of warnings regarding avelumab and MCC, causation-related considerations for affected patients, and the timeline between exposure and documented harm. The warnings for avelumab, as an immune checkpoint inhibitor, include the potential for immune-related adverse events, but the evidence does not suggest that avelumab induces MCC. The timeline between exposure to avelumab and documented harm is relevant to adverse events such as immune-related adverse events, which can occur during treatment, but not to the development of MCC itself. For patients with MCC, avelumab is a standard treatment option, and the risk of progression or lack of response is a documented concern, with approximately 50% of patients not responding or progressing on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/; https://pubmed.ncbi.nlm.nih.gov/34445385/). In summary, the evidence supports that avelumab is an approved and effective treatment for metastatic MCC, with response rates of approximately one-third in chemotherapy-refractory patients. The risk of non-response or progression is significant, and for avelumab-refractory patients, alternative treatments such as combined ipilimumab and nivolumab may offer benefit. There is no evidence in the provided sources to suggest that avelumab causes MCC; rather, it is used to treat the disease.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Does avelumab cause Merkel cell carcinoma?

No, avelumab is a treatment for Merkel cell carcinoma (MCC), not a cause. It is an immune checkpoint inhibitor approved for metastatic MCC. Studies show it can induce tumor regression in about one-third of patients, but there is no evidence that avelumab causes MCC.

What are the main risk factors for Merkel cell carcinoma?

MCC is primarily associated with chronic ultraviolet light exposure and infection with Merkel cell polyomavirus. Approximately 80% of cases are linked to the virus, while the remaining 20% are UV-induced. Immunosuppression also increases risk.

What happens if avelumab does not work for MCC?

For patients refractory to avelumab, alternative treatments such as combined ipilimumab and nivolumab may be effective. Studies show that about 50% of patients do not respond or progress on avelumab, and combination therapy can offer benefit in some cases.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.